Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2013-03-27

FDA Approved: BIDIL — Supplemental Application (Azurity Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental NDA for BIDIL (hydralazine hydrochloride and isosorbide dinitrate) from Azurity Pharmaceuticals, Inc. The action approves changes un…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BIDIL (Hydralazine hydrochloride and isosorbide dinitrate)

Snippet

SUPPL AP for BIDIL (HYDRALAZINE HYDROCHLORIDE AND ISOSORBIDE DINITRATE)